ImetelChat

The extended time frames are disappointing. But the idea of a sit down with the FDA and trying an end run around needing a dual trial for MF given the current stats, is a novel idea worth pursuing. Kudos for the crew that came up with it

Currently traveling. Will post later re conf call and abstracts. Am struck by the inclusion of a significant p value and a real attempt to establish statistical validly in MF study. Many including myself have suggested Scarlett will avoid a PIII in MF. Using matched controls even though historic, is an effort to do so. bp

I agree, this is somewhat encouraging. They probably don't have useful historical controls right now because of the differences between different hospitals' protocols and generally bad databases (HIPAA didn't help the already-backwards hospital medical databases).

But that doesn't that the necessary data doesn't exist, if they hunt it down.